Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years

Background: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood. Methods: We conducted a single-centre retrospective study and assessed...

Full description

Bibliographic Details
Main Authors: Kohei Fujita, Osamu Kanai, Hiroaki Hata, Kenjiro Ishigami, Kazutaka Nanba, Naoki Esaka, Koichi Seta, Tadashi Mio, Takao Odagaki
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Aging and Health Research
Subjects:
Covid-19
Pandemic
Molnupiravir
Older patients
Anti-viral agent
SARS-CoV-2
Online Access:http://www.sciencedirect.com/science/article/pii/S2667032123000148

Internet

http://www.sciencedirect.com/science/article/pii/S2667032123000148

Similar Items